Wenjuan Wu

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

S. Betty Yan, Victoria L. Peek, Rose T. Ajamie et al. · Investigational New Drugs · 2012 · 161 citations · Full text

Medicine, Oncology, Pharmacology +17

ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

Shripad V. Bhagwat, William T. McMillen, Shufen Cai et al. · Molecular Cancer Therapeutics · 2019 · 108 citations · Full text

Medicine, Oncology, Pharmacology +17

RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1

S-H Chen, Xutong Gong, Y Zhang et al. · Oncogene · 2017 · 73 citations

Medicine, Cancer Biology, Oncology +15

Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET

Wenjuan Wu, Bi Chen, Kelly M. Credille et al. · Clinical Cancer Research · 2013 · 68 citations · Full text

Medicine, Oncology, Pharmacology +12

Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration

Genshi Zhao, Colin F. Green, Yu‐Hua Hui et al. · Molecular Cancer Therapeutics · 2017 · 45 citations

Medicine, Oncology, Pharmacology +13